Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) have been given a consensus rating of “Moderate Buy” by the fifteen research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eleven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $56.25.

Several brokerages have recently commented on FTH. Robert W. Baird assumed coverage on shares of Sensei Biotherapeutics in a research report on Friday, June 26th. They set an “outperform” rating and a $57.00 price objective for the company. Raymond James Financial began coverage on shares of Sensei Biotherapeutics in a research note on Friday, July 31st. They issued an “outperform” rating and a $56.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Sensei Biotherapeutics in a research note on Thursday, June 4th. Wall Street Zen lowered Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 26th. Finally, JonesTrading initiated coverage on Sensei Biotherapeutics in a research note on Tuesday, August 4th. They set a “buy” rating and a $55.00 price target on the stock.

Sensei Biotherapeutics Stock Performance

Shares of Sensei Biotherapeutics stock opened at $28.27 on Friday. The stock’s 50-day simple moving average is $32.09. Sensei Biotherapeutics has a 1-year low of $7.45 and a 1-year high of $42.14. The firm has a market cap of $730.50 million, a P/E ratio of -0.20 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. Analysts forecast that Sensei Biotherapeutics will post -13.69 earnings per share for the current fiscal year.

Institutional Trading of Sensei Biotherapeutics

Hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC bought a new stake in shares of Sensei Biotherapeutics during the second quarter worth about $307,000. Renaissance Technologies LLC lifted its position in Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after acquiring an additional 20,525 shares in the last quarter. Bank of America Corp DE lifted its position in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Stempoint Capital LP acquired a new position in Sensei Biotherapeutics during the 1st quarter valued at about $4,188,000. Finally, Alyeska Investment Group L.P. acquired a new position in Sensei Biotherapeutics during the 2nd quarter valued at about $3,610,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.